help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on June 10, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2008-0247
A more recent version of this article appeared on August 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
93/8/3222    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Doghman, M.
Right arrow Articles by Lalli, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doghman, M.
Right arrow Articles by Lalli, E.
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Endocrine Oncology

Submitted on February 4, 2008
Accepted on May 29, 2008

The Tcf/{beta}-catenin antagonist PKF115–584 inhibits proliferation of adrenocortical carcinoma cells

Mabrouka Doghman, Julie Cazareth, and Enzo Lalli*

Institut de Pharmacologie Moléculaire et Cellulaire CNRS UMR 6097; and Université de Nice Sophia Antipolis, Valbonne, France

* To whom correspondence should be addressed. E-mail: ninino{at}ipmc.cnrs.fr.

Context: Mutations of the {beta}-catenin (CTNNB1) gene are frequently found in adrenocortical tumors. This has important consequences to deregulate the expression of transcriptional targets of the Wnt pathway, which may contribute to tumorigenesis.

Objective: To investigate the effect of the small-molecule inhibitor of the Tcf/{beta}-catenin complex PKF115–584 on {beta}-catenin – dependent transcription and proliferation of H295R adrenocortical tumor cells, which harbor mutations in CTNNB1 as well as in the TP53 tumor suppressor gene.

Main outcome measures: Immunofluorescence, transient transfection, proliferation assays and flow cytometric analyses were employed.

Results: Nuclear localization of {beta}-catenin and constitutive activation of {beta}-catenin – dependent transcription was observed in H295R cells. PKF115–584 dose-dependently inhibited {beta}-catenin – dependent transcription and H295R proliferation, even in the presence of increased SF-1 levels, which augment proliferation in this cell line. The drug had no effect on HeLa cells, a cell line where the {beta}-catenin pathway is not activated. PKF115–584 decreased the percentage of H295R cells in S-phase and increased the percentage of apoptotic cells.

Conclusions: Inhibitors of the Tcf/{beta}-catenin complex may reveal useful in the treatment of adrenocortical tumors where multiple genetic alterations have accumulated.


Key words: adrenal cortex • cancer • {beta}-catenin • proliferation







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society